• Breckenridge Pharmaceutical Inc., of Boca Raton, Fla., and Alembic Pharmaceuticals Ltd., of Baroda, India, settled Paragraph IV patent litigation with Novartis AG, of Basel, Switzerland, concerning rivastigmine tartrate capsules, a generic version of Novartis' Exelon.